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case-control study
L.A. Brinton, R. Hoover & J.F. Fraumeni, Jr
Environmental Epidemiology Branch, National Cancer Institute, Landow Building, Room 3C06, Bethesda,
MD 20892, USA.
Summary A study among 1960 post-menopausal breast cancer cases and 2258 controls identified through a
nation-wide screening program enabled evaluation of effects of oestrogen use on breast cancer risk. Ever use
was not associated with increased risk (RR= 1.0), but a significant trend was observed with increasing years
of use, with users of 20 or more years being at a 50% excess risk. Elevations associated with long-term use
were apparent across all menopause subgroups (natural, ovaries retained, ovaries removed). Hormones
exerted particularly adverse effects in those initiating use subsequent to a diagnosis of benign breast disease,
particularly long-term users (RR =3.0, 95% CI 1.6-5.5). There was also some indication that effects
predominated among the lower stage tumours, an observation similar to that observed for endometrial
cancer. These findings support a role for oestrogens in the aetiology of breast cancer, although risk appears to
be enhanced only after extended periods of use, and not to the extent observed for other hormonally-sensitive
tumours.
The relationship between menopausal oestrogen use
and breast cancer risk has long been of interest,
particularly given extensive evidence that
endogenous hormones are involved in aetiology
(Henderson et al., 1982) and that oestrogens can
induce mammary neoplasms in experimental
animals (IARC, 1979). Interest heightened when
Hoover et al. (1976), in a retrospective cohort study
of menopausal oestrogen users, showed that the
risk of breast cancer increased with years since
initial exposure, reaching a significant risk of 2.0
after 15 years. Subsequent case-control studies,
however, yielded conflicting results (Jick et al.,
1980; Ross et al., 1980; Hoover et al., 1981; Kelsey
et al., 1981; Hulka et al., 1982; Hiatt et al., 1984;
Kaufman et al., 1984; Nomura et al., 1986). Most
failed to find evidence of any overall excess risk,
although several indicated that long-term users
might be adversely affected. A further complication
was that hormone effects appeared to be modified
by ovarian status, but various studies disagreed on
which subgroups were at highest risk. The different
subgroups included women with a natural
menopause (Jick et al., 1980; Hulka et al., 1982),
women whose ovaries were retained (Ross et al.,
1980) and women having undergone a bilateral
oophorectomy (Hoover et al., 1981; Hiatt et al.,
1984). In addition, two large case-control studies
(Kelsey et al., 1981; Kaufman et al., 1984) failed to
identify any of these subgroups as being prone to
hormone effects.
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In 1981, we published results from a case-control
study involving 881 cases and 863 controls
identified through a nationwide screening program
(Brinton et al., 1981). Although hormone use was
not associated with any substantial overall risk,
there was some hazard suggested among women
who received hormones following bilateral
oophorectomy, obliterating the protective effect
normally associated with the operation. In this
group, risk increased with years of oestrogen use,
reaching risks of 2-3 for users of ten or more years.
Higher risks were observed among oophorecto-
mized women who used hormones in the presence of
other risk factors, including nulliparity, family
history of breast cancer, and benign breast disease.
We subsequently had the opportunity to expand
the original case-control study, concentrating on
women whose breast cancer was detected during the
latter years of the screening project. The extension
of this study more than doubled our original
sample size, enabling detailed evaluations of
hypotheses raised by the initial investigation risks
among hormone-susceptible subgroups, and
relationships of hormone use to varying disease
states.
Subjects and methods
Subjects for this case-control study participated in
the Breast Cancer Detection Demonstration Project
(BCDDP), a multi-centre breast cancer screening
program involving over 280,000 women at 29
widely dispersed centres. This program, jointly
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sponsored by the American Cancer Society and the
National Cancer Institute, recruited women
between 1973 and 1975 for a five-year program of
annual breast examinations by the combined
modalities of clinical examination, mammography,
and thermography.
Previous publications (Brinton et al., 1981;
Brinton et al., 1983) have described the
methodology of the initial case-control study
conducted among women whose breast cancer was
detected during the first several years of screening
(July 1973 through May 1977). An extension of the
study included additional cases diagnosed during
the latter three years of screening (through
November, 1980). Control subjects were chosen
from women who had not received either a
recommendation for biopsy or a biopsy during the
course of screening participation. Controls were
matched to the cases on centre, race (white, black,
oriental, other), age (same five-year group), time of
entry (same six-month period) and length of
continuation in the program (controls were required
to have at least as many years of screening as the
cases).
Home interviews were conducted by trained
interviewers. Completed interviews were obtained
from 3,351 cases (77.9% of eligible subjects) and
3,583 controls (83.0%). Reasons for non-response
included failure to trace subjects having moved
(1.7% of cases vs. 4.3% of controls), refusals (5.0%
vs. 7.8%), death (11.5% vs. 2.3%), and other
miscellaneous reasons (3.9% vs. 2.6%).
Information on menopausal hormone use
included date of first use, duration of use, date of
last use, reasons for discontinuation, names of the
pills used longest and most recently, and regimen of
the pill used longest. To aid in the recall of pill
names, subjects were shown colour photographs of
hormone brands.
The present analysis is limited to white women
(91% of those interviewed) who reported having
undergone menopause either naturally or surgically
at least three months before the date of diagnosis
(or equivalent date for controls). The type of
menopause was defined by the event that caused
the cessation of menstruation. The post-menopausal
women included in this analysis consisted of 1960
cases and 2258 controls (of whom 881 cases and
863 controls were in our previous analyses)
(Brinton et al., 1981).
Based on a standard reporting criteria, all breast
cancer cases were classified as in situ or invasive.
For the invasive cases, information on tumour
length, width, and depth was reviewed, and those
lesions less than or equal to 1 cm in greatest
dimension were classified as small invasive lesions.
A total of 1110 breast cancer cases were classified
as larger invasive cancers, 281 as small invasive
cancer, and 254 as in situ cancer; standardized
pathologic information was unavailable for 315
cases, who were analyzed separately.
For evaluating effects of an exposure factor, the
measure of association was the relative risk (RR),
as estimated by the odds ratio. Adjustment for
confounding variables was accomplished using
multivariate logistic techniques (Prentice & Pyke,
1979), deriving maximum likelihood estimates of
combined RRs and 95% confidence intervals (CI).
One-tailed tests for trend in the logistic analyses
were obtained by categorizing the exposure
variable, assigning the score j to the jth exposure
level of the categorical variable, and treating the
scored variable as a continuous variable. Logistic
regression was also used to test for the statistical
significance of interactions. Since matching was
employed in the study design, multivariate analyses
using a program for matched data were also
undertaken (Lubin, 1981). These analyses produced
results similar to those derived from the full data
set, and unmatched estimates have thus been
chosen for presentation.
Results
A total of 1029 of the cases (53%) and 1175 of the
controls (52%) reported prior use of menopausal
oestrogens, resulting in a crude RR of 1.0 (95% CI
0.9-1.2). This estimate was not confounded by a
number of breast cancer risk factors, including age
at first livebirth, age at menarche, history of breast
biopsies, family history of breast cancer, or weight.
In addition, the association was not affected by
control for other factors, such as symptoms of
menopause, smoking, or oral contraceptive use. It
was, however, necessary to consider type of
menopause and the interval since oophorectomy,
particularly in examining effects associated with
years of hormone use. Since those at lowest disease
risk (bilaterally oophorectomized women with
extended intervals since oophorectomy) had the
highest probability of being prescribed long-term
replacement oestrogens, adjustment for type of
menopause and interval since oophorectomy
resulted in notable increases in the risks associated
with durations of hormone use.
After appropriate adjustment, there was a
significant increase in risk (P<0.01) with extended
exposures, with those reporting 20 or more years of
use having a 50% excess risk (Table I). Risk was
further elevated among those using hormones 25
years or more (RR= 1.7, 95% CI 0.9-3.2), although
this estimate was based on only 28 exposed cases.
Further evidence for an effect of duration of use
was derived when years of use was entered in the
model as a continuous variable, where it showed aMENOPAUSAL OESTROGENS AND BREAST CANCER 827
Table I Relative risks of breast cancer associated with
varying parameters of menopausal hormone use
Cases Controls RR (95% CI)
Ever use
No 931 1083 1.00
Yes 1029 1175 1.03 (0.9-1.2)
Years of use
<5 486 640 0.89 (0.8-1.0)
5-9 249 259 1.09 (0.9-1.3)
10-14 159 141 1.28 (0.9-1.6)
15-19 70 74 1.24 (0.9-1.8)
20+ 49 43 1.47 (0.9-2.3)
Trend test 6.31 (P<0.01)
Years since
initial use
<10 502 591 1.03 (0.9-1.2)
10-14 236 240 1.15 (0.9-1.4)
15-19 124 148 0.95 (0.7-1.2)
20+ 145 164 0.97 (0.7-1.2)
Trend test 0.02 (P=0.45)
Age at first use
<40 129 156 1.00 (0.8-1.3)
40-44 190 226 1.01 (0.8-1.2)
45-49 326 341 1.14 (0.9-1.4)
50+ 362 420 0.99 (0.8-1.2)
RRs are adjusted for age and type of menopause; RRs
for years of use are adjusted additionally for interval since
oophorectomy.
significant (P<0.001) effect on risk. This analysis
also showed that the estimated multiplication of
breast cancer risk was 1.02 for every year of
menopausal hormone use. No pattern of risk was
apparent with years since initial use or age at first
use of hormones.
Risks according to regimen of use and type of
preparation are shown in Table II. No substantial
variation was seen according to regimen of use, the
RRs ranging from 0.7 for use every other day to
1.2 for daily use. Analysis of effects associated with
type of preparation considered both the hormone
pill used most recently as well as that used longest.
Both approaches found significant elevations in risk
associated with use of either unknown dosages of
Premarin (RRs=1.6-1.8) or diethystilbestrol (DES)
(RRs=1.6-2.0). However, for those women
reporting specific dosages of Premarin, a
medication that has distinctive colours for each
dose, there were no clear trends according to
increasing dosage for either the pill used most
recently or that used for the longest period of time.
Further analyses evaluated the relationship of
risk to combined measures of type of preparation
used longest and total years of use (Table III). This
also failed to demonstrate an effect of dose of
Premarin. However, there were increases in risk
with duration of use within the two dosage
categories comprising the majority of Premarin
usage (0.625 and 1.25mg), with a significant
increase in risk (1.9) seen for those using 0.625mg
preparations for 10 or more years. In addition,
elevations in risk were associated with long-term
use of both DES (RR=3.1) and other preparations
(RR=1.5), the majority of which were non-
conjugated oestrogens.
Since previous reports have noted varying
oestrogen effects according to ovarian status, we
examined relationships separately for women with a
natural menopause, those with a hysterectomy
without oophorectomy and those with a bilateral
oophorectomy (Table IV). There was little variation
in the effects associated with ever use, the RRs
ranging from 1.0 to 1.1. However, there was
evidence of increasing risk with extended durations
of use within all three menopause subgroups. The
effects were most striking among the naturally
menopausal women, where the trend in risk was
statistically significant (P=0.03), and the risk
associated with 15 or more years (1.7) was
statistically significant. Risks associated with long-
term use among the two other menopause groups
were elevated, although to a somewhat lesser extent
(RRs= 1.3-1.4).
Further analyses explored the interaction of years
of hormone use with a number of other risk factors
(Table V). Although none of the interactions were
significant, there was evidence that long-term (10+
years) hormone use exerted the most adverse effects
among women over the age of 55 years (RR= 1.4).
In addition, long-term use was associated with
higher risks among those reporting late ages at
menarche, early ages at first livebirth, late ages at
natural menopause, and a history of biopsy for
benign breast disease. There was no evidence of an
interaction of hormone use with a family history of
breast cancer in a first degree relative; in fact,
hormone associations were restricted to those
without a family history. RRs associated with
hormone use also did not appear to be modified by
weight, height or other measures of body mass.
In order to explore further the interaction of
hormone use with history of benign breast disease,
the timing of usage was examined (Table VI). This
demonstrated no relationship of hormone use
among those who initiated use prior to a first
biopsy for benign disease, even when use extended
beyond 10 years. However, those who started using
hormones after a diagnosis of benign breast disease
were at elevated risk compared to those who had
never used hormones, and the risk was significantly
elevated among those who continued using
hormones for 10 or more years (RR=3.0, 95% CI
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Table II Relative risks of breast cancer associated with regimen and preparation
ofmenopausal hormone use
Cases Controls RR (95% CI)
Regimen of hormone
used longest
Every day
Every other day
Cyclically
Other regimen
Unknown
Preparation used
most recently
Premarin 0.3 mg
Premarin 0.625 mg
Premarin 1.25mg
Premarin 2.5 mg
Premarin unknown dose
Premarin w/methyltestosterone
Diethylstilbestrol
Other
Unknown
Preparation used
longest
Premarin 0.3 mg
Premarin 0.625mg
Premarin 1.25mg
Premarin 2.5 mg
Premarin unknown dose
Premarin w/methyltestosterone
Diethylstilbestrol
Other
Unknown
452
34
358
109
76
61
189
389
25
55
26
42
93
149
51
178
425
30
51
25
40
90
139
456
45
423
177
74
101
257
383
41
37
27
25
114
190
60
199
492
43
39
29
28
99
186
1.17 (0.9-1.4)
0.90 (0.6-1.4)
1.00 (0.8-1.2)
0.72 (0.6-0.9)
1.19 (0.8-1.7)
0.71 (0.5-0.9)
0.87 (0.7-1.1)
1.20 (1.0-1.4)
0.74 (0.5-1.2)
1.77 (1.2-2.7)
1.18 (0.7-2.0)
1.97 (1.2-3.3)
0.98 (0.7-1.3)
0.91 (0.7-1.2)
0.99 (0.7-1.4)
1.05 (0.8-1.3)
1.02 (0.9-1.2)
0.84 (0.5-1.4)
1.55 (1.0-2.4)
1.05 (0.6-1.8)
1.64 (1.0-2.7)
1.09 (0.8-1.5)
0.86 (0.7-1.1)
All risks are relative to non-hormone users. RRs are adjusted for age and type
of menopause.
Table III Relative risks of breast cancer associated with menopausal hormone preparation used
longest and total years of use
<10 years use 10+ years use
Preparation used
longest Cases Controls RR Cases Controls RR
Premarin 0.3mg 40 45 1.04 10 14 0.76
Premarin 0.625mg 128 167 0.90 49 31 1.94a
Premarin 1.25mg 276 335 0.94 144 152 1.13
Premarin 2.5mg 20 30 0.77 10 12 1.00
Premarin unknown dose 46 35 1.57a 4 4 1.18
Premarin w/methyltestosterone 23 24 1.12 2 4 0.66
Diethylstilbestrol 29 23 1.54 11 4 3.11
Other 66 78 1.01 23 19 1.52
Unknown 107 162 0.77 25 18 1.70
All risks are relative to non-hormone users. RRs are adjusted for age, type of menopause and
interval since oophorectomy. ap<0.05.Table IV Relative risks of breast cancer associated with selected parameters of
menopausal hormone use by type of menopause
Surgical- Surgical-
Natural ovaries retained ovaries removed
Ever use
No 1.00 (650, 767) 1.00 (198, 214) 1.00 (66, 90)
Yes 1.05 (477, 541) 1.01 (287, 303) 1.14 (254, 303)
95% CI (0.9-1.2) (0.8-1.3) (0.8-1.6)
Years of use
<5 0.95 (263, 332) 0.82 (113, 149) 0.98 (108, 147)
5-9 1.05 (102, 116) 1.15 (75, 70) 1.18 (69, 70)
10-14 1.30 (62, 56) 1.16 (49, 45) 1.64 (46, 36)
15+ 1.70a (42, 28) 1.26 (45, 37) 1.43 (29, 45)
Trend test 3.91 (P=0.03) 1.55 (P=0.11) 3.66 (P=0.03)
Years since initial use
<10 1.02 (243, 292) 0.97 (131, 148) 1.31 (127, 147)
10-14 0.98 (99, 119) 1.09 (71, 69) 1.94a (62, 46)
15-19 1.16 (60, 59) 0.87 (31, 37) 0.96 (33, 47)
20+ 1.33 (59, 49) 1.09 (50, 46) 0.68 (31, 60)
Trend test 1.55 (P=0.II) 0.03 (P =0.43) 1.09 (P=0.15)
Numbers of cases, controls are shown in parentheses. RRs are adjusted for age;
RRs for years of use among the ovaries removed group are adjusted additionally
for interval since oophorectomy. ap<0.05.
Table V Hormone-associated relative risks of breast cancer associated with
years of use of menopausal hormones by selected risk factors
Years ofhormone use
Nonuser <10 10+
Age (years)
<45
45-54
55-64
65+
Age at menarche (years)
<12
12
13
14
15+
Age at first livebirth (years)
<20
20-24
25-29
30+
Nulliparous
Age at menopause (years)
<40
40-44
45-49
50-54
55+
History of breast biopsy
No
Yes
Family history of breast
cancer (first degree relative)
No
Yes
1.00 (34)
1.00 (231)
1.00 (391)
1.00 (275)
1.00 (170)
1.00 (207)
1.00 (273)
1.00 (152)
1.00 (118)
1.00 (63)
1.00 (281)
1.00 (248)
1.00 (167)
1.00 (170)
1.00 (130)
1.00 (156)
1.00 (252)
1.00 (319)
1.00 (74)
2.07 (28)
1.08 (270)
0.88 (341)
0.79 (96)
0.74 (116)
0.80 (169)
1.06 (220)
1.00 (133)
1.27 (94)
1.52 (61)
0.92 (228)
0.87 (215)
0.67 (98)
1.22 (130)
1.02 (107)
0.98 (114)
0.95 (218)
0.89 (241)
1.04 (55)
0.85 (2)
0.78 (32)
1.45k (168)
1.43 (76)
0.66 (31)
1.23 (75)
1.26 (78)
1.86a (54)
2.03a (38)
1.68 (22)
1.632 (84)
1.02 (64)
1.06 (46)
1.22 (59)
1.17 (67)
0.99 (63)
1.52a (76) 1.76a (57)
1.41 (15)
1.00 (741) 0.96 (553) 1.23 (199)
1.00 (190) 0.85 (182) 1.50 (79)
1.00 (687) 0.95 (534) 1.46a (219)
1.00 (243) 0.88 (197) 0.94 (58)
Numbers of cases are shown in parentheses. RRs are adjusted for age, type
of menopause, and interval since oophorectomy. aP<0.5.
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Table VI Relative risks of breast cancer in relation to history of benign breast
disease and timing of menopausal hormone use
History ofbiopsyfor
benign breast disease and timing
ofhormone use Cases Controls RR (95% CI)
Biopsy, no hormone use 190 167 1.00 (-)
Hormone use before first biopsy
Ever use 48 70 0.60 (0.4-0.9)
< 10 years use 29 40 0.62 (0.4-1.1)
10+ years use 19 30 0.62 (0.3-1.2)
Hormone use after first biopsy
Ever use 205 152 1.14 (0.8-1.6)
< 10 years use 148 134 0.93 (0.7-1.3)
10+ years use 57 18 3.01 (1.6-5.5)
RRs are adjusted for age and type of menopause; RRs for years of use are adjusted
additionally for interval since oophorectomy.
Associations were also examined according to
whether breast cancer was diagnosed on the first
screening examination (prevalent cases) as opposed
to subsequently (incident cases). No differences in
the associations with hormone use were apparent.
However, analyses by stage of disease indicated that
hormone effects predominated among the lower
stage tumours (Table VII). The risks associated
with ever use of hormones were 1.3 for the in situ
tumours and 1.2 for the small invasive cancers, as
opposed to 1.0 for the larger invasive tumours.
Among the lower stage tumours, there were
significant increases in risk with increasing duration
of hormone use, with RRs rising among long-term
users (10+ years) to significant risks of 1.9 and 1.5
for in situ and small invasive tumours, respectively.
In comparison, the risk of large invasive tumours
was 1.3 among long-term users. Menopausal
hormone use was not associated with any increased
risk among those tumours classified as unknown
stage. The elevated risks of in situ tumours
associated with long-term use were observed for all
menopause subgroups, ranging from 2.1 for the
naturally menopausal women to 3.0 for those
having undergone a bilateral oophorectomy. In
addition, increased risks associated with long-term
use were observed for in situ tumours detected on
the initial screening examination (prevalent cases)
as well as those detected at later exams (incident
cases).
Table VII Relative risks of breast cancer associated with menopausal hormone
disease
use by stage of
Small invasive Large invasive
In situ < Icm) (>1 cm) Unknown
(n =254) (n =281) (n= 1110) (n =315)
Ever use
No 1.00 (106) 1.00 (122) 1.00 (533) 1.00 (170)
Yes 1.26 (148) 1.19 (159) 1.02 (577) 0.80 (145)
95% Cl (0.9-1.6) (0.9-1.5) (0.9-1.2) (0.6-1.1)
Years of use
<5 0.90 (57) 0.99 (70) 0.90 (279) 0.79 (80)
5-9 1.52a (41) 1.40 (42) 1.05 (138) 0.68 (28)
10+ 1.90a (49) 1.51a (45) 1.29a (151) 0.88 (33)
Trend test 11.68 (P<0.01) 5.45 (P=0.01) 3.00 (P=0.04) 2.04 (P=0.08)
RRs are adjusted for age and type of menopause; RRs for years of use are adjusted additionally
for interval since oophorectomy. ap<0.05.MENOPAUSAL OESTROGENS AND BREAST CANCER 831
Discussion
This study found no relationship between ever use
of menopausal hormones and risk of breast cancer.
However, there was a significant trend in risk with
increasing duration of hormone use, although
elevations in risk were small, being on the order of
50% only after 15 years of use. While some further
increases in risk were observed after 25 years of
use, the maximum RR only reached 1.7. Thus, our
findings indicate that if hormone use increases
breast cancer risk, the risk is limited to relatively
long-term users and is small, at least in comparison
to the risks for oestrogen-related endometrial
cancer (Brinton et al., 1984). However, given the
extensive population exposure to menopausal
oestrogens and the frequency of breast cancer in the
general population, even a slight excess risk
associated with hormone use is cause for concern.
For instance, if the relationship is causal, a 50%
elevation in risk among oestrogen users of 15 or
more years would result in an approximate
cumulative absolute excess risk of 2% for women
aged 65-79.
Of primary interest in our study was the
evaluation of effect modification according to
ovarian status. The issue is complicated by the fact
that ovarian status influences both the risk of
breast cancer (Trichopoulos et al., 1972) and the
rates of exposure to menopausal oestrogens
(Rosenberg et al., 1979). Previous studies have
produced inconsistent findings. Ross et al. (1980)
found excess hormone risks confined to women
whose ovaries were left intact, particularly among
those with high cumulative oestrogen doses. Hoover
et al. (1981), however, in a study among pre-paid
health plan participants, observed hormone effects
to be greater in women whose ovaries were
removed, a finding similar to that derived from
previous analyses performed on a subset of the
current data (Brinton et al., 1981). In contrast, the
present study found excess risks associated with
long term use among all menopause subgroups,
failing to support earlier impressions that women
with oophorectomy are more susceptible to
hormone effects than those whose ovaries are left
intact. However, it must be emphasized that this
conclusion is based on a careful analysis of the
effects of confounding variables and particularly
the interval since oophorectomy, a variable that has
not been extensively evaluated in previous
investigations.
Thus, it seems likely that previous findings
regarding differential effects of hormones by
ovarian status may reflect the influence of
extraneous factors. Chance is also a possible
explanation, especially if oestrogen use conveys
only a modest elevation in risk, and this risk is
restricted to long-term users. In the present study,
which is the largest to date, we had (with 0.05 level
of significance) a 90% power of detecting a RR of
1.4 among hormone users of 10 years or more. The
next largest studies permitting power calculations
(Hoover et al., 1981; Kaufman et al., 1984),
however, had comparable power to detect risks in
heavily exposed subjects of only 1.8 to 2.6. The
ability to identify associations in subgroups,
including those defined by ovarian status, would
obviously be considerably less. Further complicating
the interpretation of several studies (Kelsey et al.,
1981; Kaufman et al., 1984) was the utilization of
hospital controls, which may have underestimated
relative risks associated with oestrogen use (Hoover
et al., 1978; Hulka et al., 1982; Nomura et al., 1986).
It was also of interest to determine whether
hormone effects were altered by the presence of
other risk factors, as shown in other studies, such
as a family history of breast cancer (Brinton et al.,
1981; Hoover et al., 1981; Hulka et al., 1982;
Nomura et al., 1986), nulliparity (Brinton et al.,
1981), and obesity (Sherman et al., 1983). Most
consistently identified has been a history of benign
breast disease (Hoover et al., 1976; Ross et al.,
1980; Brinton et al., 1981; Thomas et al., 1982;
Nomura et al., 1986). This interaction seems
plausible, since menopausal hormones predispose to
benign breast disease (Trapido et al., 1984;
Berkowitz et al., 1985) and benign breast disease
enhances the risk of breast cancer (Ernster, 1981).
It was thus noteworthy that we found evidence of
such an interaction, though it was dependent on the
timing of hormone use, with all of the excess risk
restricted to use after diagnosis of benign disease.
In addition, the risk was further enhanced among
those with extended durations of use, being at a
significant 3-fold excess risk compared to those
reporting no previous hormone use. A higher risk
among women whose benign breast disease
preceded first oestrogen use is directly opposite to
that noted by Hoover et al. (1976). However, our
findings were consistent with those of Thomas et al.
(1982), suggesting a promotional effect of oestrogen
use on benign breast pathology.
In contrast to previous reports we found no
evidence of interaction with either family history of
breast cancer, nulliparity, or obesity; in fact,
hormone risks were somewhat elevated among these
without a family history and either those with an
early first birth or multiple births, possibly
reflecting an enhanced ability for effects to be
detected in those at lowered disease risk. Although
there was some evidence of increased risk for
hormone users with later ages at menopause,
consistent with a common mechanistic pathway for
the two factors, the interaction was not pronounced
or significant.832 L.A. BRINTON et al.
Of special interest is our finding that hormone
effects were most pronounced for the lower stage
tumours. Although menopausal oestrogens have not
previously been investigated in terms of breast
cancer stage, Vessey et al. (1979) noted higher rates
of oral contraceptive use among women with lower
breast cancer stages, and suggested that this might
reflect better diagnostic ascertainment among those
with frequent contact with the health care system.
However, in the present study, which focussed on a
sample of volunteer participants to a screening
program, ascertainment bias was of lesser concern,
particularly since associations persisted for both
prevalent as well as incident cases. Thus, our
findings appear noteworthy, particularly given their
consistency with studies that have shown that
oestrogen effects are most apparent for lower grade
endometrial cancers (Brinton et al., 1984).
Although an inverse relationship of oestrogen use
with disease stage is opposite to what would be
expected under a growth promotion hypothesis, it is
very possible that hormones induce the
proliferation of initiated cells prior to the
appearance of in situ disease. Further assessment of
the relationship of oestrogen use to breast cancer
stage and to precursor lesions should help to clarify
the carcinogenic risks and mechanisms of action.
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